vs
Side-by-side financial comparison of ADMA BIOLOGICS, INC. (ADMA) and ASHFORD HOSPITALITY TRUST INC (AHT). Click either name above to swap in a different company.
ASHFORD HOSPITALITY TRUST INC is the larger business by last-quarter revenue ($259.0M vs $139.2M, roughly 1.9× ADMA BIOLOGICS, INC.). ADMA BIOLOGICS, INC. runs the higher net margin — 35.5% vs -26.8%, a 62.3% gap on every dollar of revenue. On growth, ADMA BIOLOGICS, INC. posted the faster year-over-year revenue change (18.4% vs -6.0%). ADMA BIOLOGICS, INC. produced more free cash flow last quarter ($34.6M vs $-86.8M). Over the past eight quarters, ADMA BIOLOGICS, INC.'s revenue compounded faster (30.4% CAGR vs -7.7%).
ADMA Biologics Inc. is a biopharmaceutical enterprise focused on the research, development, manufacturing and commercialization of specialty plasma-derived immunoglobulin therapies. It primarily operates in the United States, catering to patients with primary immunodeficiency and other immune-related disorders, healthcare providers and medical institutions across its core immune health therapeutic segment.
Ashford Hospitality Trust Inc is a U.S.-headquartered real estate investment trust focused on upper-upscale full-service hotel properties across key U.S. urban, suburban and resort markets. Its portfolio holds assets under top global hospitality brands, serving business and leisure travelers, with a focus on long-term value growth and stable shareholder returns.
ADMA vs AHT — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $139.2M | $259.0M |
| Net Profit | $49.4M | $-69.3M |
| Gross Margin | 63.8% | — |
| Operating Margin | 45.1% | -2.6% |
| Net Margin | 35.5% | -26.8% |
| Revenue YoY | 18.4% | -6.0% |
| Net Profit YoY | -55.9% | 44.2% |
| EPS (diluted) | $0.20 | $-12.85 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $139.2M | $259.0M | ||
| Q3 25 | $134.2M | $266.1M | ||
| Q2 25 | $122.0M | $302.0M | ||
| Q1 25 | $114.8M | $277.4M | ||
| Q4 24 | $117.5M | $275.5M | ||
| Q3 24 | $119.8M | $276.6M | ||
| Q2 24 | $107.2M | $316.5M | ||
| Q1 24 | $81.9M | $303.9M |
| Q4 25 | $49.4M | $-69.3M | ||
| Q3 25 | $36.4M | $-60.1M | ||
| Q2 25 | $34.2M | $-30.4M | ||
| Q1 25 | $26.9M | $-20.0M | ||
| Q4 24 | $111.9M | $-124.2M | ||
| Q3 24 | $35.9M | $-57.9M | ||
| Q2 24 | $32.1M | $50.3M | ||
| Q1 24 | $17.8M | $71.6M |
| Q4 25 | 63.8% | — | ||
| Q3 25 | 56.3% | — | ||
| Q2 25 | 55.1% | — | ||
| Q1 25 | 53.2% | — | ||
| Q4 24 | 53.9% | — | ||
| Q3 24 | 49.8% | — | ||
| Q2 24 | 53.6% | — | ||
| Q1 24 | 47.8% | — |
| Q4 25 | 45.1% | -2.6% | ||
| Q3 25 | 38.0% | 4.6% | ||
| Q2 25 | 35.1% | 16.3% | ||
| Q1 25 | 30.4% | 22.2% | ||
| Q4 24 | 32.6% | -17.8% | ||
| Q3 24 | 33.1% | 7.3% | ||
| Q2 24 | 36.6% | 42.8% | ||
| Q1 24 | 26.7% | 50.2% |
| Q4 25 | 35.5% | -26.8% | ||
| Q3 25 | 27.1% | -22.6% | ||
| Q2 25 | 28.1% | -10.1% | ||
| Q1 25 | 23.4% | -7.2% | ||
| Q4 24 | 95.2% | -45.1% | ||
| Q3 24 | 30.0% | -20.9% | ||
| Q2 24 | 29.9% | 15.9% | ||
| Q1 24 | 21.7% | 23.5% |
| Q4 25 | $0.20 | $-12.85 | ||
| Q3 25 | $0.15 | $-11.35 | ||
| Q2 25 | $0.14 | $-6.88 | ||
| Q1 25 | $0.11 | $-4.91 | ||
| Q4 24 | $0.45 | $-13.64 | ||
| Q3 24 | $0.15 | $-12.39 | ||
| Q2 24 | $0.13 | $2.50 | ||
| Q1 24 | $0.08 | $5.99 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $87.6M | $66.1M |
| Total DebtLower is stronger | $72.1M | $2.5B |
| Stockholders' EquityBook value | $477.3M | $-626.4M |
| Total Assets | $624.2M | $2.8B |
| Debt / EquityLower = less leverage | 0.15× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $87.6M | $66.1M | ||
| Q3 25 | $61.4M | $81.9M | ||
| Q2 25 | $90.3M | $100.0M | ||
| Q1 25 | $71.6M | $85.8M | ||
| Q4 24 | $103.1M | $112.9M | ||
| Q3 24 | $86.7M | $119.7M | ||
| Q2 24 | $88.2M | $121.8M | ||
| Q1 24 | $45.3M | $111.1M |
| Q4 25 | $72.1M | $2.5B | ||
| Q3 25 | $72.4M | $2.6B | ||
| Q2 25 | — | $2.6B | ||
| Q1 25 | — | $2.7B | ||
| Q4 24 | $72.3M | $2.6B | ||
| Q3 24 | — | $2.7B | ||
| Q2 24 | — | $2.8B | ||
| Q1 24 | — | $2.9B |
| Q4 25 | $477.3M | $-626.4M | ||
| Q3 25 | $431.2M | $-548.7M | ||
| Q2 25 | $398.3M | $-485.5M | ||
| Q1 25 | $373.4M | $-446.1M | ||
| Q4 24 | $349.0M | $-419.2M | ||
| Q3 24 | $231.9M | $-288.4M | ||
| Q2 24 | $188.3M | $-225.9M | ||
| Q1 24 | $153.7M | $-276.8M |
| Q4 25 | $624.2M | $2.8B | ||
| Q3 25 | $568.7M | $3.0B | ||
| Q2 25 | $558.4M | $3.1B | ||
| Q1 25 | $510.6M | $3.1B | ||
| Q4 24 | $488.7M | $3.2B | ||
| Q3 24 | $390.6M | $3.3B | ||
| Q2 24 | $376.4M | $3.3B | ||
| Q1 24 | $350.9M | $3.5B |
| Q4 25 | 0.15× | — | ||
| Q3 25 | 0.17× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.21× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $35.6M | $-15.7M |
| Free Cash FlowOCF − Capex | $34.6M | $-86.8M |
| FCF MarginFCF / Revenue | 24.8% | -33.5% |
| Capex IntensityCapex / Revenue | 0.8% | 27.5% |
| Cash ConversionOCF / Net Profit | 0.72× | — |
| TTM Free Cash FlowTrailing 4 quarters | $27.8M | $-135.5M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $35.6M | $-15.7M | ||
| Q3 25 | $13.3M | $5.5M | ||
| Q2 25 | $21.1M | $16.3M | ||
| Q1 25 | $-19.7M | $-25.0M | ||
| Q4 24 | $50.2M | $-23.6M | ||
| Q3 24 | $25.0M | $795.0K | ||
| Q2 24 | $45.6M | $8.0M | ||
| Q1 24 | $-2.2M | $-46.5M |
| Q4 25 | $34.6M | $-86.8M | ||
| Q3 25 | $-1.1M | $-226.0K | ||
| Q2 25 | $18.7M | $-3.6M | ||
| Q1 25 | $-24.4M | $-44.8M | ||
| Q4 24 | $47.5M | $-131.6M | ||
| Q3 24 | $24.0M | $-21.8M | ||
| Q2 24 | $43.6M | $-22.9M | ||
| Q1 24 | $-4.6M | $-80.4M |
| Q4 25 | 24.8% | -33.5% | ||
| Q3 25 | -0.8% | -0.1% | ||
| Q2 25 | 15.3% | -1.2% | ||
| Q1 25 | -21.2% | -16.2% | ||
| Q4 24 | 40.4% | -47.8% | ||
| Q3 24 | 20.0% | -7.9% | ||
| Q2 24 | 40.7% | -7.2% | ||
| Q1 24 | -5.6% | -26.5% |
| Q4 25 | 0.8% | 27.5% | ||
| Q3 25 | 10.7% | 2.1% | ||
| Q2 25 | 2.0% | 6.6% | ||
| Q1 25 | 4.1% | 7.2% | ||
| Q4 24 | 2.3% | 39.2% | ||
| Q3 24 | 0.9% | 8.2% | ||
| Q2 24 | 1.9% | 9.8% | ||
| Q1 24 | 2.9% | 11.2% |
| Q4 25 | 0.72× | — | ||
| Q3 25 | 0.36× | — | ||
| Q2 25 | 0.62× | — | ||
| Q1 25 | -0.73× | — | ||
| Q4 24 | 0.45× | — | ||
| Q3 24 | 0.70× | — | ||
| Q2 24 | 1.42× | 0.16× | ||
| Q1 24 | -0.12× | -0.65× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ADMA
| ADMA Bio Manufacturing Segment | $123.1M | 88% |
| Other | $16.0M | 12% |
AHT
| Occupancy | $190.2M | 73% |
| Food And Beverage | $51.8M | 20% |
| Hotel Other | $16.6M | 6% |
